Acide Phytique, Calcium Magnesium Inositol Hexaphosphate, Calcium Phytate, Fytic Acid, Hexaphosphate d'Inositol, Hexaphosphate d'Inositol de Calcium Magnésium, Inositol Hexaphosphate, InsP6, Phytate, Phytate de Calcium, Phytic Acid.


Overview Information

IP-6, inositol hexaphosphate, is a vitamin-like substance. It is found in humans, animals, and many plants, especially cereals, nuts, and legumes. It can also be made in a laboratory.

Some people use IP-6 to treat and prevent cancer, to reduce side effects of cancer treatment, for anemia, diabetes, and many other conditions, but there is no good scientific evidence to support these uses.

In manufacturing, IP-6 is added to food to keep it from spoiling.

How does it work?

IP-6 might help treat and prevent cancer by slowing down the production of cancer cells. It might also bind to certain minerals, decreasing the risk of colon cancer. IP-6 is also an antioxidant.


Uses & Effectiveness?

Insufficient Evidence for

  • Damage to the immune system caused by cancer drug treatment. Early research shows that taking IP-6 by mouth or applying it to the skin might help to reduce some side effects of cancer drug treatment.
  • Gout. Gout is caused by high levels of a chemical called uric acid. Early research in people with high levels of uric acid shows that taking IP-6 can lower uric acid levels. It's unclear if this improves symptoms of gout.
  • Treating and preventing cancer.
  • Preventing heart attacks.
  • Other conditions.
More evidence is needed to rate the effectiveness of IP-6 for these uses.

Side Effects

Side Effects & Safety

When taken by mouth: IP-6 is LIKELY SAFE when used in amounts found in foods. IP-6 is POSSIBLY SAFE when used as a medicine, short-term. Taking IP-6, 600 mg two times per day for up to 2 weeks, appears to be safe. There isn't enough reliable information to know if IP-6 is safe when used long-term or in larger amounts.

Special Precautions & Warnings:

Pregnancy and breast-feeding: IP-6 is LIKELY SAFE for pregnant and breast-feeding women when used in food amounts. But there isn't enough reliable information to know if larger medicinal amounts of IP-6 are safe to use when pregnant or breast-feeding. Stay on the safe side and stick to food amounts.

Clotting disorders: IP-6 might slow blood clotting. If you have a clotting disorder, use IP-6 with caution.

Iron-deficiency anemia: IP-6 binds with iron in the gastrointestinal (GI) tract. This reduces the amount of iron that the body absorbs from food and supplements.

Weak and brittle bones (osteoporosis): IP-6 binds with calcium in the gastrointestinal (GI) tract. This reduces the amount of calcium that the body absorbs from food and supplements. This might worsen osteoporosis.

Surgery: Since IP-6 might slow blood clotting, there is a concern that it might increase the risk of extra bleeding during and after surgery. Stop using IP-6 at least 2 weeks before a scheduled surgery.



Moderate Interaction

Be cautious with this combination

  • Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with IP-6

    IP-6 nicotinate might slow blood clotting. Taking IP-6 along with medications that also slow clotting might increase the chances of bruising and bleeding.
    Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.



The appropriate dose of IP-6 depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for IP-6. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References


  • Bacic I, Druzijanic N, Karlo R, Skific I, Jagic S. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J Exp Clin Cancer Res. 2010;29:12. View abstract.
  • Challa A, Rao DR, Reddy BS. Interactive suppression of aberrant crypt foci induced by azoxymethane in rat colon by phytic acid and green tea. Carcinogenesis 1997;18:2023-6. View abstract.
  • Deliliers GL, Servida F, Fracchiolla NS, et al. Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells. Br J Haematol 2002;117:577-87. View abstract.
  • Graf E, Eaton JW. Antioxidant functions of phytic acid. Free Radic Biol Med 1990;8:61-69. View abstract.
  • Grases F, Costa-Bauza A. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. Anticancer Res 1999;19:3717-22.. View abstract.
  • Grases F, Garcia-Gonzalez R, Torres JJ, Llobera A. Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol 1998;32:261-5.. View abstract.
  • Grases F, Simonet BM, Vucenik I, et al. Absorption and excretion of orally administered inositol hexaphosphate (IP(6) or phytate) in humans. Biofactors. 2001;15(1):53-61. View abstract.
  • Ikenaga T, Kakumoto K, Kohda N, Yamamoto T. Effect of Inositol Hexaphosphate (IP6) on Serum Uric Acid in Hyperuricemic Subjects: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Plant Foods Hum Nutr. 2019 Sep;74(3):316-321. View abstract.
  • Jariwalla RJ. Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent. Anticancer Res 1999;19:3699-3702. View abstract.
  • Proietti S, Pasta V, Cucina A, et al. Inositol hexaphosphate (InsP6) as an effective topical treatment for patients receiving adjuvant chemotherapy after breast surgery. Eur Rev Med Pharmacol Sci. 2017;21(2 Suppl):43-50. View abstract.
  • Saied IT, Shamsuddin AM. Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. Anticancer Res 1998;18:1479-84. View abstract.
  • Sandberg AS, Brune M, Carlsson NG, et al. Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. Am J Clin Nutr 1999;70:240-6. View abstract.
  • Sandstrom B, Sandberg AS. Inhibitory effects of isolated inositol phosphates on zinc absorption in humans. J Trace Elem Electrolytes Health Dis 1992;6:99-103. View abstract.
  • Shamsuddin AM, Elsayed AM, Ullah A. Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 1988;9:577-80. View abstract.
  • Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agent. Life Sci 1997;61:343-54. View abstract.
  • Shamsuddin AM, Vucenik I. Mammary tumor inhibition by IP6: a review. Anticancer Res 1999;19:3671-4. View abstract.
  • Shamsuddin AM, Yang GY. Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 1995;16:1975-9. View abstract.
  • Shamsuddin AM. Metabolism and cellular functions of IP6: a review. Anticancer Res 1999;19:3733-6. View abstract.
  • Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996;96:1027-39. View abstract.
  • Tantivejkul K, Vucenik I, Eiseman J, Shamsuddin AM. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. Breast Cancer Res Treat 2003;79:301-12. View abstract.
  • Thompson LU, Zhang L. Phytic acid and minerals: effect on early markers of risk for mammary and colon carcinogenesis. Carcinogenesis 1991;12:2041-5. View abstract.
  • Vucenik I, Passaniti A, Vitolo MI, et al. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 2004;25:2115-23. View abstract.
  • Vucenik I, Podczasy JJ, Shamsuddin AM. Antiplatelet activity of inositol hexaphosphate. Anticancer Res 1999;19:3689-93. View abstract.
  • Vucenik I, Zhang ZS, Shamsuddin AM. IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res 1998;18:4091-6. View abstract.
  • Wilson MS, Bulley SJ, Pisani F, Irvine RF, Saiardi A. A novel method for the purification of inositol phosphates from biological samples reveals that no phytate is present in human plasma or urine. Open Biol. 2015;5(3):150014. View abstract.
  • Zhou JR, Erdman JW Jr. Phytic acid in health and disease. Crit Rev Food Sci Nutr 1995;35:495-508. View abstract.

Vitamins Survey

Have you ever purchased IP-6?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

This survey is being conducted by the WebMD marketing sciences department.Read More

More Resources for IP-6

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty .